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ABSTRACT 
Recently, controlled release drug delivery has become the standards in the modern pharmaceutical design and intensive research has been undertaken in 
achieving much better drug product effectiveness, reliability and safety. Oral Extended release drug delivery medication will continue to account for the 
largest share of drug delivery systems. The extended release formulations are the type of formulations which will improves the therapeutic index of drug 
concentration. These formulations make the drug available over extended time period after oral/Parenteral administration. The extended release product will 
optimize therapeutic effect and safety of a drug at the same time improving the patient convenience and compliance. Prior to the development of these  major 
dosage forms, it is essential that pertain fundamental physical and chemical properties of the drug molecule and other divided properties of the drug powder 
are determined. This information decides many of the subsequent events and approaches in formulation development. 
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INTRODUCTION 
Sustained  release,  sustained  action,  controlled  release, 
extended action, timed release, depot and repository dosage 
forms are the terms used to identify drug delivery systems 
that are designed to achieve a prolonged therapeutic effect by 
continuously releasing medication over an extended period of 
time after the administration of single dose. In the case of 
injectable drugs this period may vary from days to months. In 
the case of orally administered forms, this period is measured 
in hours and is critically depends on the residence time of the 
dosage form in the GIT. The term “controlled release” has 
become  associated  with  those  systems  from  which 
therapeutic  agents  may  be  automatically  delivered  at 
predefined  rates  over  a  long  period  of  time.  The  rate 
controlled drug delivery systems are capable of controlling 
the  rate  of  drug  delivery,  sustaining  the  duration  of 
therapeutic activity, and /or targeting the delivery of drug to a 
tissue.  Although  these  advancements  have  led  to  the 
development  of  several  novel  drug  delivery  systems  that 
could revolutionalize the method of medication and provide a 
number  of  therapeutic  benefits,  they  also  create  some 
confusion  in  terminology  between  ‘controlled  release’  and 
‘sustained release’
1. 
 
 
Figure:1 
 
The  term  “sustained  release”  has  been  constantly  used  to 
describe a pharmaceutical dosage form formulated to retard 
the release of a therapeutic agent such that its appearance in 
the systemic circulation is delayed and/or prolonged and its 
plasma profile is sustained in duration (i.e. not necessarily at 
a predetermined rate). The onset of the pharmacologic action 
is often delayed, and the duration of its therapeutic agent is 
sustained. 
The  term  “controlled  release”  on  the  other  hand,  has  a 
meaning that goes beyond the scope of sustained drug action. 
It also implies a predictability in the drug release kinetics, 
which  means  that  the  release  of  drug  ingredient  from  a 
controlled-release  drug  delivery  system  proceeds  at  a  rate 
profile  that  is  not  only  predictable  kinetically  but  also 
reproducible from one unit to another
2. 
The Concept of Preformulation 
Almost all drugs are marketed as tablets, capsules or both. 
Prior to the development of these major dosage forms, it is 
essential  that  pertain  fundamental  physical  and  chemical 
properties of the drug molecule and other divided properties 
of the drug powder are determined. This information decides 
many of the subsequent events and approaches in formation 
development.  This  first  learning  phase  is  known  as  pre-
formulation.  It can be defined as an investigation of physical 
and chemical properties of new drug substance alone or in 
combination  with  other  excipient.  Pre-formulation  is  also 
phase  of  research  &  development  process  where  research 
scientist  characterize  physical,  chemical  and  mechanical 
aspect of new drug under investigation in order to developed 
stable safe & effective dosage form Pre-formulation involves 
the  application  of  biopharmaceutical  principles  to  the 
physicochemical  parameters  of  drug  substance  are 
characterized  with  the  goal  of  designing  optimum  drug 
delivery system. 
Before  beginning  the  formal  pre-formulation  programs  the 
pre-formulation scientist must consider the following factors: 
·  The amount of drug available. 
·  The  physicochemical  properties  of  the  drug  already 
known. 
·  Therapeutic category and anticipated dose of compound. 
·  The nature of information, a formulation should have or 
would like to have. 
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Pre-formulation drug characterization in a structured 
program 
UV Spectroscopy  
The  first  requirement  of  any  pre-formulation  study  is  the 
development of a simple analytical method for quantitative 
estimation in subsequent steps. Most of drugs have aromatic 
rings  and/or  double  bonds  as  part  of  their  structure  and 
absorb  light  in  UV  range,  UV  spectroscopy  being  a  fairly 
accurate  and  simple  method  is  a  performed  estimation 
technique at early pre-formulation stages. The absorption Co-
efficient of the drug can be determined by the formula: 
E =  AF / X  
Where,  A = Asborbance 
    F = dilution factor 
  X = weight of drug (mg) 
It is now possible to determine concentration of drug in any 
solution by measuring absorbance
3. 
   C =   AF / E mg/ ml 
Characterization of drug molecules is very important step at 
the pre-formulation phase of product development. Following 
studies  are  conducted  as  basic  pre-formulation  studies, 
special  studies  are  conducted  depending  on  the  type  of 
dosage form and the type of drug molecules. 
·  Solubility determination 
·  pKa determination 
·  Partition co-efficient 
·  Crystal properties and polymorphism 
·  Practical size, shape and surface area. 
·  Chemical stability profile. 
 Solubility Determination 
The  solubility  of  drug  is  an  important  physicochemical 
property because it effects the bioavailability of the drug, the 
rate of drug resale into dissolution medium and consequently, 
the therapeutic efficiency of the pharmaceutical product. The 
solubility of the molecules in various solvents is determined 
as a first step. This information is valuable is developing a 
formulation.  Solubility  is  usually  determined  in  variety  of 
commonly  used  solvents  and  some  oils  if  the  molecule  is 
lipophillic.  The solubility of material is usually determined 
by  the  equilibrium  solubility  method,  which  employs  a 
saturated  solution  of  the  material,  obtained  by  stirring  an 
excess  of  material  in  the  solvent  for  a  prolonged  until 
equilibrium achieved
6  
Common solvents used for solubility determination are  
Water,  Polyethylene  Glycols,  Propylene  Glycol,  Glycerin, 
Sorbitol,  Ethyl  Alcohol,  Methanol,  Benzyl  Alcohol, 
Isopropyl Alcohol, Tweens, Polysorbates, Castor Oil, Peanut 
Oil, Sesame Oil, Buffer at various pHs
6 . 
Aqueous Solubility  
The  availability  of  a  drag  is  always  limited  and  the 
preformulation  scientist  may  only  have  50  mg.  Solubility 
dictates  the  ease  with  which  formulation   for  oral  gavages 
and intravenous injection studies in animals are obtained the 
pKa allies the informed of pH to maintain solubility and to 
choose salts required to achieve good bioavailability from the 
solid state and improve stability and powder properties
7. 
Intensic   Solubility (Co)  
An  increase  in  solubility  in  acid  compared  to  aqueous 
solubility suggests a weak base and an increase in alkali, a 
weak  acid.  An  increase  in  acidic  and  alkaline  solubility 
suggest either impotence or zuitter ion behavior. In this case 
there will be two pKa’s, one acidic & one basic. When the 
pavrity  of  the  drug  sample  can  be  assured  the  solubility 
obtained in acid for a weak acid or albali for a weak base can 
be  assured  to  be  the  instensic  solubility  (Co.)  i.e.  the 
fundamental  solubility  when  completely  unionized.  The 
solubility should ideally be measured at two temperature. 
1)  4C  to  ensure  physical  stability  and  entered  short  term 
storage and chemical stability unit more definitive data are 
available. The minimum density of water occurs at 4C. This 
leads  to a minimum aqueous solubility. 
2) 37 
oC to support biopharmaceutical evaluation.   
pKa Determination 
Determination of the dissociation content for a drug capable 
of ionization within a ph rang of 1 to 10 is important since 
solubility  and   consequently  absorption,  cab  be  altered  by 
orders  of  magnitude  with   changing  pH.  The  Henderson – 
Hasseslebach  equation  provides  an  estimate  of  the  ionized 
and un ionized durg concentration at a particular pH. 
For acidic compounds 
pH = pKa + log  (un-ionized drug]) / [ionized drug]) 
Partition Coefficient  
Partition  Coefficient  (oil/  water)  is  a  measure  of  a  drug’s 
lipophilicity  and  an  indication  of  its  ability  to  cross  cell 
membranes.  It  is  defined  as  the  ratio  of  unionized  drug 
distributed  between  the  organic  and  aqueous  phases  at 
equilibrium. 
P o/w = (C oil / C water) equilibrium. 
For series of compounds, the partition coefficient can provide 
an empiric handle in screening for some biologic properties. 
For  drug  delivery,  the  lipophilic/  hydrophilic  balance  has 
been shown to be a contributing factor for the rate and extent 
of drug absorption. Although partition coefficient data alone 
does not provide understanding of in vivo absorption, it does 
provide a means of characterizing the lipophilic/ hydrophilic 
nature of the drug. Since biological membranes are lipoidal in 
nature. The rate of drug transfer for passively absorbed drugs 
is directly related to the lipophilicity  of the molecule. The 
partition  coefficient  is  commonly  determined  using  an  oil 
phase  of  octanol  or  chloroform  and  water.  Drugs  having 
values if P much greater than 1 are classified as lipophilic, 
whereas those with partition coefficient much less than 1 are 
indicative of a hydrophilic drug. Although it appears that the 
partition coefficient may be the best predictor of absorption 
rate,  the  effect  id  dissolution  rate,  pKa  and  solubility  on 
absorption must not be neglected
8  
Dissolution  
The dissolution rate of the a drug is only important where it is 
the  rate  limiting  step  in  the  absorption  process.  Kaplan 
suggested that provided the solubility of a drug exceeded to 
mg/  ml  at  pH,  7  no  bioavailability  or  distinction  related 
problems were to be expected. Below / mg/ ml such problems 
were  quite  possible  and  salt  formation  could  improve 
absorption  and  solubility  by  controlling  the  pH  of  the 
microenvironment,  independently  of  the  drug  and  dosage 
forms position within the GI Tract
10 . 
Intrinsic Dissolution Rate 
When dissolution is controlled solely by diffusion the rate of 
diffusion  is  directly  proportional  to  the  saturated 
concentration of the drug in solution under these conditions 
the rate constant K1 is defined by 
K1 = 0.62 D
2/3 v 
1/6 w
1/2 
Where, V is the kinemative viscosity 
W is the anguter velocity of a rotating disc of drug. 
Common Ion Effect 
A  common  ion  significantly  reduces,  the  solubility  of  a 
slightly soluble electrolyte. The ‘selling out’ results from the 
removal  of  water  molecules  as  solvent owing  to  the 
completing  hydration  of  other  ions.  The  reverse  process D. Akhilesh et al. IRJP 2012, 3 (5) 
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‘salting  in’  qries  with  large  anions  e.g.  benzoate,  salivate 
which open the water structure. These hydro topics increase 
the solubility of properly water soluble compounds such as 
diazepam. 
Melting Point  
The  melting  point  of   a  drug  can  be  measured  using three 
techniques  
1)Capillary Melting 
2)Hot Stage Microcopy 
3)Differential scanning calorinetry or thermal Analysis. 
Capillary Melting 
Capillary melting gives information about the melting range 
but it is different to assign an accurate melting point. 
Hot Stage Microcopy 
This the issued observation of melting under a microscope 
equipped with a heated and lagged sample stage. The heating 
rate  is  controllable  and  up  to  three  transitions  can  e-
registered. 
Differential Scanning Calorimeltry and thermal analysis  
Differential  thermal  analysis  (DTA)  measures  the 
temperature difference between the sample and a reference as 
a function of temperature or time when heating at a constant 
rate differential scanning calorinetry (DSC) is similar to DTA 
except  that  the  instrument  measures  the  amount  of  energy 
required to keep the sample at the same temperature as the 
reference i.e. it measures the enthalpy of transition
11. 
Crystal Properties and Polymorphism 
Many drug substance can exit in more than one crystalline 
from with different space lattice arrangements. This property 
is  known  as  polymorphism.  Polymorphs  generally  have 
different  melting  points,  x-ray  diffraction  patterns 
and solubility  even  though  they  are   chemically  identical. 
Differences  in  the  dissolution  rates  and  solubilities  of 
different  polymorphic  forms  of  a  given  drug  are  very 
commonly  observed.  When  the  absorption  of  a  drug  is 
dissolution rate limited, a more soluble and faster-dissolving 
from  may  be  utilized  to  improve  the  rate  and  extent  of 
bioavailability.For  drugs  pane  to  degradation  in  the  solid 
state,  physical  form  of  the  drug  influences  degradation. 
Selection of a polymorph that is chemically more stable is a 
solution  in  many  cases.  Different  polymorph  also  lead  to 
different morphology, tensile strength and density of power 
bed  which  all  contribute  of  compression  characteristics  of 
materials.  Some  investigation  of  polymorphism  and  crystal 
habit  of  a  drug  substance  as  it  relates  to  pharmaceutical 
processing is desirable during its Preformulation evaluation 
especially when the active ingredient is expected to constitute 
the bulk of the tablet mass. Although a drug substance may 
exist in two or more polymorphic forms, only one form is 
theromdynamically  stable  at  a  given  temperature  and 
pressure. The other forms would convert to the stable form 
with  time.  In  general,  the  stable  polymorph  exhibits  the 
highest  melting  point  ,  the  lowest  solubility,  and  the 
maximum  chemical  stability.  Various  techniques  are 
available  for  the  investigation  of  the  solid   state.  These 
include microscopy (including hot stage microcopy), infrared 
spectrophotometry,  single-crystal  x-ray  and  x-ray  power 
diffraction, thermal analysis, and dilalometry. 
Particle Size, Shape and Surface Area 
Bulk  flow,  formulation  homogeneity,  and  surface-area 
controlled  processes  such  as  dissolution  and  Surface 
morphology of the drug particles. In general, each new drug 
candidate  should  be  tested  during  Preformulation  with  the 
smallest particle size as is practical to facilitate preparation of 
homogeneous samples and maximize the drug’ s surface area 
for interactions. Various chemical and physical properties of 
drug substances are affected by their particle size distribution 
and shapes. The effect is not only on the physical properties 
of  solid  drugs  but  also,  in  some  instances,  on  their 
biopharmaceutical  behavior.  It  is  generally  recognized  that 
poorly soluble drugs showing a dissolution- rate limiting step 
in the absorption process will be more readily bio available 
when administered in a finely subdivided state rather than as 
a coarse material. In case of tablets, size and shape influence 
the flow and the mixing efficiency of powders and granules. 
Size  can  also  be  a  factor  in  stability:  fine  materials  are 
relatively more open to attack from atmospheric oxygen, the 
humidity,  and  interacting  axcipients  than  are  coarse 
materials
12. 
·  Determination of particle size 
·  Determination of surface area 
Particle size Determination 
Though microscopy is the simplest technique of estimating 
size  ranges  and  shapes,  it  is  to  slow  for  quantitative 
determination the material is best observed as a suspension in 
non dissolving fluid. Saving is less useful technique at pre-
formulation storage due to lack of bulk material. Andreason  
pipette  is  based  on  the rate  difference  of  sedimentation  of 
different particles, but techniques like this are seldom used 
due  to  their  tedious  nature  instruments  based  on  light 
scattering, (Royco), light blockage (HIAC) and blockage of 
electrical conductivity path (coulter counter) are available. 
Surface Area Determination 
Surface  area  is  most  commonly  determined  based  on 
brunaver  emette  teller  (BET)  theory  of  adsorption.  Most 
substances  adsorb  a  mono  molecular  layer  of  gas  under 
certain conditions of partial pressure of gas and temperature. 
Knowing the monolayer capacity of adsorbent and the area of 
absorbale  molecule,  the  surface  area  can  be  calculated  the 
adsorption process is carried out with nitrogen at-195 degree 
Celsius at a partial pressure attainable when nitrogen is in a 
30% temperature with an inert gas (helium). The adsorption 
takes place by virtue of vander wall’s forces. 
Power Flow Properties 
When  limited  amounts  of  drugs  are  available  Power  flow 
properties can be evaluated by measurements of bulk density 
and angle of repose. Changes in particles size, and shape are 
generally very important an increase in crystal size or a more 
uniform  shape  will  lead  to  a  small  angle  or  repose and  a 
smaller Carr’s index.  
Bulk Density 
Knowledge  of  absolute  and  bulk  density  of  the  drug 
substance is Very useful in Having some idea  as to the size 
of final dosage form the density of solids also of affects their 
flow Properties Carr’s compressibility index can be used to 
predict the flow properties based on density measurement. 
Carr’s index (%)    =   Tapped density – Pored density *100 
    Tapped density 
A similar index has been defined by Hausner: 
Hausner ratio   =   Tapped density 
  Pored density 
Angle of repose 
The maximum angle which is formed b/w the surface of a 
pile of powder and horizontal surface is called the angle of 
repose. 
Chemical stability profile 
Preformulation  stability  studies  are  usually  the  first 
quantitative  assessment of chemical stability of a new drug. 
These  studies  include  both  solution  and  solid  state D. Akhilesh et al. IRJP 2012, 3 (5) 
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experiments  under  condition  typical  for  the  handing, 
formulation, storage, and administration of a drug candidate 
as well as stability in presence of other recipients. 
Factor effecting chemical stability critical in rational dosage 
form  design  include  temperature,  pH  and  dosage  form 
diluents. The method of sterilization of potential product will 
be largely dependent on the temperature stability of the drug. 
Drugs  having  decreased  stability  at  elevated  temperatures 
cannot be sterilized by autoclaving but must be sterilized by 
another  means,  e.g.,  filtration.  The  effect  of  pH  on  drug 
stability  is  important  in  the  development  of  both  oral 
administration  must  be  protected  from  the  highly  acidic 
environment  of  the  stomach.  Buffer  selection  for  potential 
dosage  forms  will  be  largely  based  on  the  stability 
characteristic of the drug. 
·  Solid state stability Solution phase stability 
·  Compatibility  studies  :  stability  in  the  Presence 
of excipients 
·  Typical stability protocol for new Chemical Entity 
Solid state stability 
Chemical  instability  normally  results  from  either  of  the 
following  reaction  :-  hydrolysis,  oxidation,  photolysis  and 
pyrolysis, Chemical structure of the drug is the determination 
of drug to either of these attacks. Esters and lactase and to 
lesser extent, amides are to prone to solvolysis Instauration or 
electron  rich  centre  in  the  structure  make  the  molecule 
vulnerable  for  free  radical  mediated  or  photo-catalysed 
oxidation. physical properties of drugs. Amorphous materials 
are less stable than their crystalline forms. Denser materials 
are more stable to ambient stress. 
Elevated temperature studies 
The elevated temperatures commonly used are 40, 50, and 60 
degree centigrade with ambient humidity. The samples stored 
at  highest  temperature  are  observed  weekly  for  physical 
and chemical  changes  and  compared  to  an  appropriate 
control.  If  a  substantial  change  is  seen,  samples  stored  at 
lower temperature are examined. If no changesisseen after 30 
days  at  60  degree  centigrade,  the  stability  prognosis  is 
excellent. 
Stability under high humidity conditions 
Solid  drug  samples  can  be  exposed  to  different  relative 
humidity  conditions  by  keeping  them  in  laboratory 
desiccators  containing  saturated  solutions  of  various  salts. 
The closed desiccators in turn are kept in oven to provide 
constant temperature. The preformulation data of this nature 
are useful in determining if the material should be protected 
and stored in controlled low humidity environment or if non 
aqueous solvent be used during formulation. 
Photolytic stability 
Many drugs fade or dorpen on exposure light. Though the 
extent  of  degradations  small  and  limited  to  the  exposed 
surface  area,  it  presents  anaesthetic  problem.  Exposure  of 
drug 400 and 900 foot-candles of illumination for 4 and 2 
week periods respectively is adequate to provide some idea of 
photosensitivity. Resulting data may be useful in determining 
if an amber colored container is required or if color masking 
bye should be used in the formulation. 
Stability to Oxidation  
Drug’s sensitivity to oxidation can be examined by exposing 
it  to  atmosphere  of  high  oxygen  tension.  Usually  a  40% 
oxygen  atmosphere  allows  for rapid  evaluation.  A  shallow 
layer  of  drug  exposed  to  a  sufficient  headspace  volume 
ensures that the system is not oxygen limited. Samples are 
kept  in  desiccators  equipped  with  three-way  stop  cocks, 
which are alternatively  evacuated and flooded with desired 
atmosphere. The process is repeated 3 or 4 times to ensure 
100%  desired  atmosphere.  Results  may  be  useful  in 
predicting if an antioxidant is required in the formulation or if 
the final product should be packaged under inert atmospheric 
conditions. 
Compatibility studies 
The knowledge of drug excipients interaction is useful for the 
formulation  to  select  appropriate  excipients.  The  described 
preformulation  screening  of  drug  excipients  interaction 
requires  only  5mg  of  drug  in  a  50%  mixture  with  the 
excipients  to  maximize  the  likelihood  of  obscuring  an 
interaction. Mixtures should be examined under nitrogen to 
ultimate oxidation and paralytic effect at a standard heating 
rate on DSC, over a temperature range, which will encompass 
any thermal changes due to both the drug and appearance or 
disappearance  one  or  more  peaks  in  themogrames  of  drug 
excipient mixtures are considered of indication of interaction. 
Solution phase stability 
As  compared  with  the  dry  form,  the  degradation  is  much 
rapid in solution form. It is important ascertain that the drug 
doesn’t  degrade  when  exposed  to  GI  fluid.  The  pH  based 
stability study, using different stimulator GI condition can be 
designed.  A  poor  solution  stability  of  drug  may  urge  the 
formulator to choose a less soluble salt form, provided the 
bioavailability is not compromised 
Absorption behavior 
It is essential to test the in vivo behavior of the new drug for 
successful formulation of a dosage from good bioavailability. 
Partial  in  vivo  and  in  vitro  test  are  designed  to  study 
pharmacokinetic profile of the drug. 
Factors affecting Controlled Release Dosage Forms  
Dose Size 
If an oral product has a dose size greater that 0.5gm it is a 
poor candidate for sustained release system, Since addition of 
sustaining dose and  possibly the sustaining mechanism will, 
in  most  cases  generates  a  substantial  volume  product  that 
unacceptably large. 
Aqueous Solubility 
Most of drugs are weak acids or bases, since the unchanged 
form  of  a  drug  preferentially  permeates  across  lipid 
membranes  drugs  aqueous  solubility  will  generally  be 
decreased by conversion to an unchanged form for drugs with 
low  water  solubility  will  be  difficult  to  incorporate  into 
sustained release mechanism. The lower limit on solubility 
for  such  product  has  been  reported  0.1mg/ml.  drugs  with 
great water solubility are equally difficult to incorporate in to 
sustained  release  system.  pH  dependent  solubility, 
particularly in the physiological pH range, would be another 
problem  because  of  the  variation in pH  throughout the  GI 
tract and hence variation in dissolution rate. 
Partition Coefficient 
Partition  coefficient  is  generally  defined  as  the  fraction  of 
drug in an oil phase to that of an adjacent aqueous phase. 
Accordingly  compounds  with  relatively  high  partition 
coefficient are predominantly lipid soluble and consequently 
have very low aqueous solubility. Compounds with very low 
partition  coefficients  will  have  difficulty  in  penetrating 
membranes  resulting  poor  bioavailability.  Typical 
relationship between drug activity and partition Coefficient 
K, generally known as Hansh Correlation. D. Akhilesh et al. IRJP 2012, 3 (5) 
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.  
Pka:  It  is  the  relationship  between  Pka  of  compound  and 
absorptive  environment.  Presenting  drug  in  an  unchanged 
form  is  adventitious  for  drug  permeation  but  solubility 
decrease as the drug is in unchanged form 
Drug Stability  
Orally administered drugs can be subject to both acid base 
hydrolysis  and  enzymatic  degradation.  Degradation  will 
proceed at the reduced rate for drugs in the solid state, for 
drugs  that  are  unstable  in  stomach,  systems  that  prolong 
delivery  ever  the  entire  course  of  transit  in  GI  tract  are 
beneficial. Compounds that are unstable in the small intestine 
may  demonstrate  decreased  bioavailability  when 
administered form a sustaining dosage from. This is because 
more drug is delivered in small intestine and hence subject to 
degradation 
Molecular size and diffusivity  
The ability of drug to diffuse through membranes its so called 
diffusivity  &  diffusion  coefficient  is  function  of  molecular 
size  (or  molecular  weight).Generally,  values  of  diffusion 
coefficient for intermediate molecular weight drugs, through 
flexible  polymer range  from 10-8 to  10-9  cm2  /  sec.  with 
values on the order of 10-8 being most common for drugs 
with  molecular  weight  greater  than  500,  the  diffusion 
coefficient  in  many  polymers  frequently  are  so  small that 
they are difficult to quantify i.e. less than 16-12 cm2/sec.  
Thus high molecular weight drugs and / or polymeric drugs 
should be expected to display very slow release kinetics in 
sustained  release  device  using  diffusion  through  polymer 
membrane. 
Biological Half Life 
The  usual  goal  of  an  oral  sustained  release  product  is  to 
maintain therapeutic blood levels over an extended period. To 
action  this,  drug  must  enter  in  the  circulation  of 
approximately the same rate of which it is eliminated. The 
elimination rate is quantitatively described by half-life (t1/2). 
Therapeutic  compounds  with  short  half  lives  are  excellent 
candidates for sustained release preparations. Since this can 
reduce  dosing  frequency.  In  general  drugs  with  half-lives 
shorter  than  3hrs  are  poor  candidates  of  sustained  release 
dosage forms of dose size will increase as well as compounds 
with long half  lives, more  than  8 hrs  are also not  used in 
sustained  release  forms  because  their  effect  is  already 
sustained. 
Absorption 
The rate, extent and uniformity of absorption of a drug are 
important  factors  when  considered  its  formulation  into  a 
sustained release  system.  As  the rate  limiting  step in  drug 
delivery from a sustained-release system is its release from a 
dosage form, rather than absorption. Rapid rate of absorption 
of drug, relative to its release is essential if the system is to be 
successful. It we assume that transit time of drug  must in the 
absorptive  areas  of  the  GI  tract  is  about  8-12  hrs.  The 
maximum half life for absorption should be approximately 3-
4 hrs. Otherwise device will pass out of potential absorption 
regions before drug release is complete. 
 
Distribution 
The distribution of drugs into tissues can be important factor 
in  the  overall  drug  elimination  kinetics.  Since  it  not  only 
lowers the concentration of circulating drug but it also can be 
rate limiting in its equilibrium with blood and extra vascular 
tissue, consequently apparent volume  of distribution assumes 
different  values  depending  on  time  course  of  drug 
disposition.  For  design  of  sustained/  controlled  release 
products, one must have information of disposition of drug. 
CONCLUSION 
Preformulation  studies  have  a  significant  part  to  play  in 
anticipating  formulation  problems  and  identifying  logical 
path in both liquid and solid dosage form technology.  The 
need for adequate drug solubility can not be overemphasized. 
The most appropriate salt for development. Stability studies 
in solution will indicate the feasibility of parental or other 
liquid dosage form and can identify methods of stabilization. 
In parallel solid-state stability by DSC, TLC and HPLC in the 
presence of tablet and capsule excipient will indicate the most 
acceptable vehicles for solid dosage form. 
By comparing the physicochemical properties of each drug 
candidate  with  in  a  therapeutic  group,  the  preformulation 
scientist  can  assist  the  synthetic  chemist  to  identify  the 
optimum  molecule,  provide  the  biologist  with  suitable 
vehicles  to  elicit  pharmacological  response  and  advise  the 
bulk chemist about the selection and production of the best 
salt  with  appropriate  particle  size  and  morphology  for 
subsequent processing. 
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